Medication
Taro-Esomeprazole
DIN 02423987 · Sun Pharma Canada Inc Likely a generic
What it is
- Active ingredients
- Esomeprazole — 40 mg
- Form and route
- Tablet (Delayed-Release) · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2014-10-09
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
- Nexium - 40MG
- Apo-Esomeprazole
- Esomeprazole
- Teva-Esomeprazole
- Esomeprazole
- Sandoz Esomeprazole
- MYL-Esomeprazole
- M-Esomeprazole
- Esomeprazole
- PMSC-Esomeprazole DR
- Riva-Esomeprazole
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026Off-formulary interchangeable Part III-B
Ontario has designated this product interchangeable with a brand product, but it is not an ODB benefit — Part III-B, Off-Formulary Interchangeable. Ontario does not pay for it under the benefit list.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 40mg and will substitute one for another at a pharmacy counter in Ontario.
- Apo-Esomeprazole 02339102Apotex Inc
- Esomeprazole 02442507Sivem Pharmaceuticals ULC
- Esomeprazole 02520702Jamp Pharma Corporation
- M-Esomeprazole 02520117Mantra Pharma Inc
- MYL-Esomeprazole 02479427Mylan Pharmaceuticals ULC
- Nexium - 40MG 02244522Astrazeneca Canada Inc
- PMSC-Esomeprazole DR 02528487Pharmascience Inc
- Sandoz Esomeprazole 02460939Sandoz Canada Incorporated
- Teva-Esomeprazole 02423863Teva Canada Limited
Ontario lists 1 further product in this group that is not currently marketed in Canada. It is not shown.
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Alimentary tract and metabolism
- ATC code
- A02BC05
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of A02BC05, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Health Canada has published a recall or safety alert naming this product. Read it on Health Canada’s own site, and speak to a pharmacist before changing anything about how you take this medication.
Health Canada says: Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada.
Matched on the product name at the start of the notice.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Taro-Esomeprazole → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.